Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Catalyst Biosciences, Inc.
Develops therapeutics for hemophilia and inflammatory diseases
South San Francisco, CA
NASDAQ: CBIO
Contact:
Jeff Himawan
Acquisition
Acquired by: Targacept
Exit date: August 20, 2015
Related News
Catalyst Biosciences Completes Merger with Targacept
Catalyst Biosciences Announces Positive Results From a Phase I Clinical Trial
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Catalyst Biosciences Announces Agreement with MedImmune to Develop Engineered Protease Therapeutics
Catalyst Biosciences and Wyeth Pharmaceuticals Announce Worldwide Collaboration
Catalyst Biosciences Raises $40M in Series C Financing